ProCE Banner Series

Practical Guidance on Modern Chronic ITP Therapeutics: A Blueprint to Improve Patient Outcomes and Quality of Life

This 2-hour interactive live webinar will provide perspectives from experts on how to develop individualized strategies to achieve optimal treatment outcomes and quality of life in the management of patients with chronic immune thrombocytopenic purpura.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses managing patients with chronic ITP.

All Events

Practical Guidance on Modern Chronic ITP Therapeutics: A Blueprint to Improve Patient Outcomes and Quality of Life

Upcoming Events

October

02

2024

7:00 PM - 9:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Tara Azizi, MSN, AGPCNP-BC, CRNP

Division of Classical Hematology
Hospital of The University of Pennsylvania
Philadelphia, Pennsylvania

ProCE Banner Faculty
Lucus W. Enslin, MSN, FNP-BC

Nurse Practitioner
Classical Hematology
APP Gen Onc Education and Onboarding Coordinator
Teaching Associate, UW Medicine
Fred Hutchinson Cancer Center
Seattle, Washington

ProCE Banner Faculty
Jennifer Mead, PA-C

Hematology Physician Associate
Massachusetts General Hospital
Boston, Massachusetts

Topics

Immune Thrombocytopenic Purpura

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Idiopathic thrombocytopenic purpura (ITP).

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses managing patients with chronic ITP. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate clinical trial evidence and factors to consider in the selection of intensified therapy in newly diagnosed patients with chronic ITP
  • Develop individualized strategies for the second-line treatment of ITP unresponsive/no longer responsive to steroids based on efficacy and safety data and including long-term evidence, expert guidance, and patient/caregiver preferences and needs
  • Compare the mechanisms of action and the evidenced-based use in clinical practice of newer vs existing agents for chronic/persistent ITP
  • Identify emerging agents and clinical trials of targeted therapies for chronic ITP, to better inform discussions with patients
  • Apply enhanced communication strategies to increase patient engagement in shared decision-making and to identify challenges to optimal outcomes, including treatment intolerance, quality-of-life issues, and barriers to clinical trial enrollment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours, including 2.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 2.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supported by an educational grant from Sobi, Inc.